Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1926988 | 1.00 | KMT2A (0.41) | KMT2ACYP1A2GAACYP2C9PKM | |
| SCHEMBL1927300 | 1.00 | KMT2A (0.41) | KMT2ACYP1A2GAACYP2C9PKM | |
| SCHEMBL21688721 | 0.89 | KLK7 (0.38) | KMT2ACYP1A2GAACYP2C9PKM | |
| SCHEMBL20511574 | 0.89 | KLK7 (0.38) | KMT2ACYP1A2GAACYP2C9PKM | |
| SCHEMBL18651138 | 0.89 | KLK7 (0.38) | KMT2ACYP1A2GAACYP2C9PKM | |
| SCHEMBL28345701 | 0.89 | KLK7 (0.38) | KMT2ACYP1A2GAACYP2C9PKM | |
| SCHEMBL18651155 | 0.88 | KLK7 (0.37) | KMT2ACYP1A2GAACYP2C9PKM | |
| SCHEMBL18651143 | 0.88 | KLK7 (0.37) | KMT2ACYP1A2GAACYP2C9PKM | |
| SCHEMBL18631717 | 0.88 | KLK7 (0.37) | KMT2ACYP1A2GAACYP2C9PKM | |
| SCHEMBL18651153 | 0.88 | KLK7 (0.37) | KMT2ACYP1A2GAACYP2C9PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348517-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2023-11-02 | — | — | US | disclosed |
| US-20230348517-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2023-11-02 | — | — | US | disclosed |
| US-11643429-B2 | Compounds and methods for the treatment of ocular disorders | Azura Ophthalmics Ltd. (IL) | 2023-05-09 | — | — | US | disclosed |
| US-11643429-B2 | Compounds and methods for the treatment of ocular disorders | Azura Ophthalmics Ltd. (IL) | 2023-05-09 | — | — | US | disclosed |
| US-11548899-B2 | Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-01-10 | — | — | US | disclosed |
| CN-109071562-B | Fused 1, 4-oxazepine and related analogs as BET bromodomain inhibitors | 密执安大学评议会 | 2022-03-22 | — | — | CN | disclosed |
| EP-3955937-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-02-23 | — | — | EP | disclosed |
| CN-114007625-A | Compounds and methods for treating ocular diseases | 阿祖拉眼科有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20210230205-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2021-07-29 | — | — | US | disclosed |
| US-20210188870-A1 | FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2021-06-24 | — | — | US | disclosed |
| US-7595401-B2 | Therapeutic compounds and their use in cancer | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595401-B2 | Therapeutic compounds and their use in cancer | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| EP-2038041-A2 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | Myriad Genetics, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-7449486-B2 | Antiproliferative agents; anticancer agents; autoimmune disease; antiarthritic agents; graft versus host disease; inflammatory bowel disorders | ARRAY BIOPHARMA INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080182992-A1 | Antiproliferative agents; anticancer agents; antiinflammatry agents; restenosis; graft versus host disease; autoimmune disease; antiarthritic agents | ARRAY BIOPHARMA, INC. | 2008-07-31 | — | — | US | disclosed |
| US-20080096860-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2007134298-A2 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20060100161-A1 | Antiproliferative agents; anticancer agents; autoimmune disease; antiarthritic agents; graft versus host disease; inflammatory bowel disorders | ARRAY BIOPHARMA INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MCL1, TP53, TUBB3 | KMT2A 3222/4885CYP1A2 1576/4885GAA 170/4885 |
| US-20080182992-A1 | Antiproliferative agents; anticancer agents; antiinflammatry agents; restenosis; graft versus host disease; autoimmune disease; antiarthritic agents | KIF5B, KIF2C, KIFC1 | KMT2A 845/4885CYP1A2 4542/4885GAA 1602/4885 |
| US-20210188870-A1 | FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | KMT2A 175/4885CYP1A2 3403/4885GAA 2661/4885 |
| US-20210230205-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | SERPINB1, KLKB1, MPO | KMT2A 3746/4885CYP1A2 2260/4885GAA 261/4885 |
| US-20060100161-A1 | Antiproliferative agents; anticancer agents; autoimmune disease; antiarthritic agents; graft versus host disease; inflammatory bowel disorders | KIF5B, KIF2C, KIFC1 | KMT2A 462/4885CYP1A2 4030/4885GAA 1625/4885 |
| US-11643429-B2 | Compounds and methods for the treatment of ocular disorders | SERPINB1, KLKB1, MPO | KMT2A 3746/4885CYP1A2 2260/4885GAA 261/4885 |
| US-20080096860-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | KMT2A 4526/4885CYP1A2 4184/4885GAA 1910/4885 |
| US-11548899-B2 | Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors | BRD4, BRD3, BRD2 | KMT2A 175/4885CYP1A2 3403/4885GAA 2661/4885 |
| US-20230348517-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | SERPINB1, KLKB1, MPO | KMT2A 3746/4885CYP1A2 2260/4885GAA 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.